The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Luckily for you, we at StockStory have no conflicts of interest - our sole job is to help you find genuinely promising companies. Keeping that in mind, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals.
Northrop Grumman (NOC)
Consensus Price Target: $644.45 (33.1% implied return)
Responsible for the development of the first stealth bomber, Northrop Grumman (NYSE: NOC) specializes in providing aerospace, defense, and security solutions for various industry applications.
Why Do We Think NOC Will Underperform?
- Organic sales performance over the past two years indicates the company may need to make strategic adjustments or rely on M&A to catalyze faster growth
- Estimated sales growth of 5.9% for the next 12 months is soft and implies weaker demand
- Earnings per share lagged its peers over the last five years as they only grew by 2.4% annually
At $484.34 per share, Northrop Grumman trades at 17.3x forward P/E. Dive into our free research report to see why there are better opportunities than NOC.
Baxter (BAX)
Consensus Price Target: $28.73 (19.7% implied return)
With a history dating back to 1931 and products used in over 100 countries, Baxter International (NYSE: BAX) provides essential healthcare products including dialysis therapies, IV solutions, infusion systems, surgical products, and patient monitoring technologies to hospitals and clinics worldwide.
Why Do We Pass on BAX?
- Constant currency growth was below our standards over the past two years, suggesting it might need to invest in product improvements to get back on track
- Sales were less profitable over the last five years as its earnings per share fell by 8.5% annually, worse than its revenue declines
- Negative returns on capital show management lost money while trying to expand the business
Baxter is trading at $24.00 per share, or 11.1x forward P/E. To fully understand why you should be careful with BAX, check out our full research report (it’s free).
Renasant (RNST)
Consensus Price Target: $48.14 (23.8% implied return)
Founded in 1904 during a time when the South was rebuilding its economy, Renasant (NYSE: RNST) is a regional bank holding company that offers banking, wealth management, insurance, and specialized lending services throughout the Southeast.
Why Does RNST Worry Us?
- Estimated net interest income growth of 3.9% for the next 12 months implies demand will slow from its five-year trend
- Annual earnings per share growth of 4.9% underperformed its revenue over the last five years, showing its incremental sales were less profitable
- 3% annual tangible book value per share growth over the last two years was slower than its banking peers
Renasant’s stock price of $38.90 implies a valuation ratio of 0.9x forward P/B. Check out our free in-depth research report to learn more about why RNST doesn’t pass our bar.
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
